This study evaluated the effectiveness and safety of improving depressive symptoms by applying tDCS for 6 weeks to patients with mild to moderate depression.

Patients received tDCS for 30 minutes with an intensity of 1.5 to 2 mA. tDCS was applied over the left (anode) and right (cathode) dorsolateral prefrontal cortex (DLPFC) 5~7 times a week and they were evaluated every 2weeks through questionnaires.

Inclusion Criteria:

• Has a diagnosis of a major depressive disorder as confirmed by the DSM-V and MINI (without psychotic features)
• Patients with a K-BDI-II score of 14 or more and 28 or less
• In the case of patients who have previously administered antidepressants, antipsychotics, and anticonvulsants for at least 1 week, Patients with sufficient drug treatment periods of at least 5 times the drug half-life.

Exclusion Criteria:

• Patients diagnosed with Axis I disorders other than major depressive disorder
• Patients diagnosed with other depressive disorders besides major depressive disorder
• Patients who have attempted suicide within 6 months of screening
• Patients who are considered to have problems with EEG and DC stimulation electrode attachment due to scalp deformity, inflammatory reaction, or other dermatological problems
• Patients judged to have other reasons for prohibition of use of tDCS medical devices
• Patients currently taking antidepressants